CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
10500 ETCTN Phase 1/Expansion Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma Adult CIRB - Early Phase Emphasis
10504 ETCTN A Randomized Phase 2 Study of Atezolizumab with or without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) Adult CIRB - Early Phase Emphasis
10505 ETCTN A Phase 1/2 Trial of Selinexor and Temozolomide in Recurrent Glioblastoma Adult CIRB - Early Phase Emphasis
10507 ETCTN A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma Adult CIRB - Early Phase Emphasis
10508 ETCTN A Phase 1 Study of Nivolumab in Combination with ASTX727 in B-cell lymphoma (NHL or HL) with an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Adult CIRB - Early Phase Emphasis
10509 ETCTN A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination with the CDK4/6 Inhibitor Abemaciclib in Patients with NUT Carcinoma and Other Solid Tumors Adult CIRB - Early Phase Emphasis
10512 ETCTN A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer Adult CIRB - Early Phase Emphasis
10517 ETCTN An Open Label, Randomized Phase II Study Neoadjuvant Erdafitinib with or without Atezolizumab in Cisplatin-Ineligible Patients with Muscle Invasive Bladder Cancer (NERA) Adult CIRB - Early Phase Emphasis
10522 ETCTN A Phase 1 Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma Adult CIRB - Early Phase Emphasis
10525 ETCTN A Phase 1b Trial of ZEN003694 (ZEN-3694) with Pembrolizumab and Nab-Paclitaxel in Patients with Metastatic Triple-Negative Breast Cancer Adult CIRB - Early Phase Emphasis